Prostate cancer therapy outcome prediction: are miRNAs a suitable guide for therapeutic decisions?

Abstract

AbstractBackgroundRadical prostatectomy, radiotherapy, chemotherapy, and androgen‐deprivation therapy are among the most common treatment options for different forms of prostate cancer (PCa). However, making therapeutic decisions is difficult due to the lack of reliable prediction markers indicating therapy outcomes in clinical practice. The involvement of miRNAs in all mechanisms of the PCa development and their easy detection characterize them as attractive PCa biomarkers. Although there are extensive data on the role of miRNAs in PCa therapy resistance and sensitivity development, the issues of whether they could be used as a guide for therapy choice and, if so, how we can progress toward this goal, remain unclear. Thus, generalizable reviews and studies which summarize, compare, and analyze data on miRNA involvement in responses to different types of PCa therapies are required.ObjectivesData on the involvement of miRNAs in therapy responses, on the role of cross‐miRNA expression in different therapies, and on miRNA targets were analyzed in order to determine the miRNA‐related factors which can lend perspective to the future development of personalized predictors of PCa sensitivity/resistance to therapies.Materials and methodsThe data available on the miRNAs associated with different PCa therapies (resistance and sensitivity therapies) are summarized and analyzed in this study, including analyses using bioinformatics resources. Special attention was dedicated to the mechanisms of the development of therapy resistance.Results and discussionA comprehensive combined analysis of the current data revealed a panel of miRNAs that were shown to be most closely associated with the PCa therapy response and were found to regulate the genes involved in PCa development via cell proliferation regulation, epithelial‐mesenchymal transition (EMT), apoptosis, cell‐cycle progression, angiogenesis, metastasis and invasion regulation, androgen‐independent development, and colony formation.ConclusionThe selected miRNA‐based panel has the potential to be a guide for therapeutic decision making in the effective treatment of PCa.